{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:46:15Z","timestamp":1793645175823,"version":"4.5.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA047967"],"award-info":[{"award-number":["R01DA047967"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00213-025-06988-4","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:56:24Z","timestamp":1765414584000},"page":"2351-2367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Individual differences in behavioral effects of xylazine and opioid-xylazine mixtures in male rats"],"prefix":"10.1007","volume":"243","author":[{"given":"Kristen L.","family":"Woodhouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-7013","authenticated-orcid":false,"given":"Jun-Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"6988_CR1","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.drugalcdep.2023.110993","volume":"253","author":"P Acosta-Mares","year":"2023","unstructured":"Acosta-Mares P, Violante-Soria V, Browne T Jr., Cruz SL (2023) Xylazine potentiates the lethal but not the rewarding effects of Fentanyl in mice. Drug Alcohol Depend 253:110993","journal-title":"Drug Alcohol Depend"},{"key":"6988_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addicn.2024.100155","author":"ML Bedard","year":"2024","unstructured":"Bedard ML, Huang X-P, Murray JG, Nowlan AC, Conley SY, Mott SE, Loyack SJ, Cline CA, Clodfelter CG, Dasgupta N, Krumm B, Roth BL, McElligott ZA (2024) Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism. Addict Neurosci. https:\/\/doi.org\/10.1016\/j.addicn.2024.100155","journal-title":"Addict Neurosci"},{"key":"6988_CR3","doi-asserted-by":"crossref","unstructured":"Bender BN, Carew JM, Bedard ML, McElligott ZA, Besheer J (2025) Xylazine potentiates the interoceptive effects of Fentanyl in male and female rats. Psychopharmacology (Berl)","DOI":"10.1101\/2025.02.07.637099"},{"key":"6988_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000324537","volume":"87","author":"S Bhalla","year":"2011","unstructured":"Bhalla S, Andurkar SV, Gulati A (2011) Study of adrenergic, imidazoline, and endothelin receptors in clonidine-, morphine-, and oxycodone-induced changes in rat body temperature. Pharmacology 87:169\u2013179","journal-title":"Pharmacology"},{"key":"6988_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103397","volume":"392","author":"K Cakir","year":"2025","unstructured":"Cakir K, Etkins J, Nguyen ML, Gonzalez K, Vivas Casanova GE, Walker EA (2025) Antagonism of the antinociceptive effects of fentanyl and the veterinary anesthetic xylazine in mice. J Pharmacol Exp Ther 392:103397","journal-title":"J Pharmacol Exp Ther"},{"key":"6988_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.2042-7158.1996.tb05983.x","volume":"48","author":"A Capasso","year":"1996","unstructured":"Capasso A, Di Giannuario A, Loizzo A, Pieretti S, Sorrentino L (1996) Dexamethasone reduced clonidine-induced hypoactivity in mice. J Pharm Pharmacol 48:615\u20138","journal-title":"J Pharm Pharmacol"},{"key":"6988_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1211\/0022357011775587","volume":"53","author":"A Capasso","year":"2001","unstructured":"Capasso A, Loizzo A (2001) Clonidine-induced antinociception and locomotor hypoactivity are reduced by dexamethasone in mice. J Pharm Pharmacol 53:351\u2013360","journal-title":"J Pharm Pharmacol"},{"key":"6988_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/15563657908989878","volume":"15","author":"SG Carruthers","year":"1979","unstructured":"Carruthers SG, Nelson M, Wexler HR, Stiller CR (1979) Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol 15:281\u2013285","journal-title":"Clin Toxicol"},{"key":"6988_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.neuropharm.2015.08.010","volume":"99","author":"AJ Chabot-Dore","year":"2015","unstructured":"Chabot-Dore AJ, Millecamps M, Naso L, Devost D, Trieu P, Piltonen M, Diatchenko L, Fairbanks CA, Wilcox GL, Hebert TE, Stone LS (2015a) Dual allosteric modulation of opioid antinociceptive potency by alpha2A-adrenoceptors. Neuropharmacology 99:285\u2013300","journal-title":"Neuropharmacology"},{"key":"6988_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bph.12695","volume":"172","author":"AJ Chabot-Dore","year":"2015","unstructured":"Chabot-Dore AJ, Schuster DJ, Stone LS, Wilcox GL (2015b) Analgesic synergy between opioid and alpha2-adrenoceptors. Br J Pharmacol 172:388\u2013402","journal-title":"Br J Pharmacol"},{"key":"6988_CR11","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","volume":"240","author":"S Choi","year":"2023","unstructured":"Choi S, Irwin MR, Kiyatkin EA (2023) Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology 240:1561\u20131571","journal-title":"Psychopharmacology"},{"key":"6988_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/s41386-023-01782-2","volume":"49","author":"S Choi","year":"2024","unstructured":"Choi S, Irwin MR, Noya MR, Shaham Y, Kiyatkin EA (2024) Combined treatment with naloxone and the alpha2 adrenoceptor antagonist atipamezole reversed brain hypoxia induced by a fentanyl-xylazine mixture in a rat model. Neuropsychopharmacology 49:1104\u20131112","journal-title":"Neuropsychopharmacology"},{"key":"6988_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0022-3565(25)23948-9","volume":"235","author":"FC Colpaert","year":"1985","unstructured":"Colpaert FC, Janssen PA (1985) Discriminative stimulus properties of xylazine in rat: discriminability and effects of putative alpha-2 adrenoceptor agonists and antagonists. J Pharmacol Exp Ther 235:521\u2013527","journal-title":"J Pharmacol Exp Ther"},{"key":"6988_CR14","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.7326\/M23-2001","volume":"176","author":"J D\u2019Orazio","year":"2023","unstructured":"D\u2019Orazio J, Nelson L, Perrone J, Wightman R, Haroz R (2023) Xylazine adulteration of the Heroin-Fentanyl drug supply: a narrative review. Ann Intern Med 176:1370\u20131376","journal-title":"Ann Intern Med"},{"key":"6988_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/BF00464790","volume":"83","author":"J De Vry","year":"1984","unstructured":"De Vry J, Koek W, Slangen JL (1984) Effects of drug-induced differences in reinforcement frequency on discriminative stimulus properties of fentanyl. Psychopharmacology 83:257\u2013261","journal-title":"Psychopharmacology"},{"key":"6988_CR16","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00213-014-3436-2","volume":"231","author":"KB Freeman","year":"2014","unstructured":"Freeman KB, Naylor JE, Prisinzano TE, Woolverton WL (2014) Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology 231:2751\u20132758","journal-title":"Psychopharmacology"},{"key":"6988_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, Shover C (2022) Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend 233:109380","journal-title":"Drug Alcohol Depend"},{"key":"6988_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3109\/15563658108990293","volume":"18","author":"AG Gallanosa","year":"1981","unstructured":"Gallanosa AG, Spyker DA, Shipe JR, Morris DL (1981) Human xylazine overdose: a comparative review with clonidine, phenothiazines, and tricyclic antidepressants. Clin Toxicol 18:663\u2013678","journal-title":"Clin Toxicol"},{"key":"6988_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","volume":"31","author":"S Greenland","year":"2016","unstructured":"Greenland S, Senn SJ, Rothman KJ, Carlin JB, Poole C, Goodman SN, Altman DG (2016) Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol 31:337\u2013350","journal-title":"Eur J Epidemiol"},{"key":"6988_CR20","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.21037\/jtd.2017.09.14","volume":"9","author":"A Hazra","year":"2017","unstructured":"Hazra A (2017) Using the confidence interval confidently. J Thorac Dis 9:4125\u20134130","journal-title":"J Thorac Dis"},{"key":"6988_CR21","doi-asserted-by":"crossref","unstructured":"Hill K, Heimer R, Sue KL (2025) Everybody\u2019s Liking It-Intentional Use of Xylazine in Fentanyl Among People Who Use Drugs. Subst Use Misuse: 1\u20138","DOI":"10.1080\/10826084.2025.2549499"},{"key":"6988_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2025.174052","volume":"254","author":"M Hochstetler","year":"2025","unstructured":"Hochstetler M, Dodge A, Chakraborty S, Jeffers A, Mitra S (2025) Xylazine co-administration influences the rewarding properties of heroin and withdrawal in male rats. Pharmacol Biochem Behav 254:174052","journal-title":"Pharmacol Biochem Behav"},{"key":"6988_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/jat\/25.4.245","volume":"25","author":"U Hoffmann","year":"2001","unstructured":"Hoffmann U, Meister CM, Golle K, Zschiesche M (2001) Severe intoxication with the veterinary tranquilizer xylazine in humans. J Anal Toxicol 25:245\u2013249","journal-title":"J Anal Toxicol"},{"key":"6988_CR24","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1002\/med.22050","volume":"44","author":"ME Hovah","year":"2024","unstructured":"Hovah ME, Holzgrabe U (2024) Bivalent and bitopic ligands of the opioid receptors: the prospects of a dual approach. Med Res Rev 44:2545\u20132599","journal-title":"Med Res Rev"},{"key":"6988_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","volume":"27","author":"J Johnson","year":"2021","unstructured":"Johnson J, Pizzicato L, Johnson C, Viner K (2021) Increasing presence of xylazine in heroin and\/or Fentanyl deaths, Philadelphia, Pennsylvania, 2010\u20132019. Inj Prev 27:395\u2013398","journal-title":"Inj Prev"},{"key":"6988_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1124\/mol.64.6.1317","volume":"64","author":"BA Jordan","year":"2003","unstructured":"Jordan BA, Gomes I, Rios C, Filipovska J, Devi LA (2003) Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol 64:1317\u20131324","journal-title":"Mol Pharmacol"},{"key":"6988_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","volume":"72","author":"M Kariisa","year":"2023","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA (2023) Illicitly manufactured Fentanyl-involved overdose deaths with detected Xylazine - United States, January 2019-June 2022. MMWR Morb Mortal Wkly Rep 72:721\u2013727","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6988_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1037\/pha0000670","volume":"32","author":"SN Khatri","year":"2024","unstructured":"Khatri SN, Sadek S, Kendrick PT, Bondy EO, Hong M, Pauss S, Luo D, Prisinzano TE, Dunn KE, Marusich JA, Beckmann JS, Hinds TD, Gipson CD (2024) Xylazine suppresses Fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. Exp Clin Psychopharmacol 32:150\u2013157","journal-title":"Exp Clin Psychopharmacol"},{"key":"6988_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0028-3908(03)00080-7","volume":"44","author":"J Lahdesmaki","year":"2003","unstructured":"Lahdesmaki J, Sallinen J, MacDonald E, Sirvio J, Scheinin M (2003) Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype. Neuropharmacology 44:882\u2013892","journal-title":"Neuropharmacology"},{"key":"6988_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/a0013088","volume":"16","author":"SS Negus","year":"2008","unstructured":"Negus SS, Schrode K, Stevenson GW (2008) Mu\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386\u2013399","journal-title":"Exp Clin Psychopharmacol"},{"key":"6988_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/syn.21923","volume":"70","author":"A Ozcetin","year":"2016","unstructured":"Ozcetin A, Cevreli B, Uzbay T (2016) Investigation of the role of alpha-2 adrenergic receptors on prepulse inhibition of acoustic startle reflex in rats. Synapse 70:501\u2013507","journal-title":"Synapse"},{"key":"6988_CR32","first-page":"e40983","volume":"15","author":"J Pergolizzi Jr","year":"2023","unstructured":"Pergolizzi J Jr., LeQuang JAK, Magnusson P, Miller TL, Breve F, Varrassi G (2023) The new stealth drug on the street: A narrative review of xylazine as a street drug. Cureus 15:e40983","journal-title":"Cureus"},{"key":"6988_CR33","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/jcpt.13462","volume":"46","author":"JV Pergolizzi Jr","year":"2021","unstructured":"Pergolizzi JV Jr, Dahan A, Ann LeQuang J, Raffa RB (2021) Overdoses due to Fentanyl and its analogues (F\/FAs) push naloxone to the limit. J Clin Pharm Ther 46:1501\u20131504","journal-title":"J Clin Pharm Ther"},{"key":"6988_CR34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S0022-3565(25)38424-7","volume":"266","author":"MJ Picker","year":"1993","unstructured":"Picker MJ, Yarbrough J, Hughes CE, Smith MA, Morgan D, Dykstra LA (1993) Agonist and antagonist effects of mixed action opioids in the pigeon drug discrimination procedure: influence of training dose, intrinsic efficacy and interanimal differences. J Pharmacol Exp Ther 266:756\u2013767","journal-title":"J Pharmacol Exp Ther"},{"key":"6988_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/jat\/9.5.234","volume":"9","author":"A Poklis","year":"1985","unstructured":"Poklis A, Mackell MA, Case MES (1985) Xylazine in human-tissues and fluids in a case of fatal drug-abuse. J Anal Toxicol 9:234\u2013236","journal-title":"J Anal Toxicol"},{"key":"6988_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/10826084.2024.2409720","volume":"60","author":"MK Reed","year":"2025","unstructured":"Reed MK, Esteves Camacho T, Olson R, Grover Z, Rapoza T, Larson MJ (2025) Xylazine\u2019s impacts on the community in Philadelphia: perspectives of people who use opioids and harm reduction workers. Subst Use Misuse 60:100\u2013107","journal-title":"Subst Use Misuse"},{"key":"6988_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100074","volume":"4","author":"MK Reed","year":"2022","unstructured":"Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL (2022) Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips. Drug and Alcohol Dependence Reports 4:100074","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"6988_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106966","volume":"197","author":"KJ Rehrauer","year":"2023","unstructured":"Rehrauer KJ, Cunningham CW (2023) IUPHAR review - bivalent and bifunctional opioid receptor ligands as novel analgesics. Pharmacol Res 197:106966","journal-title":"Pharmacol Res"},{"key":"6988_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/life11111217","author":"R Root-Bernstein","year":"2021","unstructured":"Root-Bernstein R, Churchill B (2021) Co-evolution of opioid and adrenergic ligands and receptors: shared, complementary modules explain evolution of functional interactions and suggest novel engineering possibilities. Life. https:\/\/doi.org\/10.3390\/life11111217","journal-title":"Life"},{"key":"6988_CR40","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.2174\/0929867321666140826120604","volume":"21","author":"R Root-Bernstein","year":"2014","unstructured":"Root-Bernstein R, Dillon PF (2014) A common molecular motif characterizes extracellular allosteric enhancers of GPCR aminergic receptors and suggests enhancer mechanism of action. Curr Med Chem 21:3673\u20133686","journal-title":"Curr Med Chem"},{"key":"6988_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010272","author":"R Root-Bernstein","year":"2018","unstructured":"Root-Bernstein R, Turke M, Subhramanyam UKT, Churchill B, Labahn J (2018) Adrenergic agonists bind to adrenergic-receptor-like regions of the mu opioid receptor, enhancing morphine and methionine-enkephalin binding: a new approach to \u201cbiased opioids\u201d? Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19010272","journal-title":"Int J Mol Sci"},{"key":"6988_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/2042098617744161","volume":"9","author":"R Rzasa Lynn","year":"2018","unstructured":"Rzasa Lynn R, Galinkin JL (2018) Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 9:63\u201388","journal-title":"Ther Adv Drug Saf"},{"key":"6988_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2024.104527","volume":"110","author":"JD Shaykin","year":"2024","unstructured":"Shaykin JD, Denehy ED, Martin JR, Chandler CM, Luo D, Taylor CE, Sunshine MD, Turner JR, Alilain WJ, Prisinzano TE, Bardo MT (2024) Targeting alpha(1)- and alpha(2)-adrenergic receptors as a countermeasure for fentanyl-induced locomotor and ventilatory depression. Environ Toxicol Pharmacol 110:104527","journal-title":"Environ Toxicol Pharmacol"},{"key":"6988_CR44","first-page":"60","volume":"40","author":"KL Smiler","year":"1990","unstructured":"Smiler KL, Stein S, Hrapkiewicz KL, Hiben JR (1990) Tissue response to intramuscular and intraperitoneal injections of ketamine and xylazine in rats. Lab Anim 40:60\u201364","journal-title":"Lab Anim"},{"key":"6988_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1280289","volume":"14","author":"MA Smith","year":"2023","unstructured":"Smith MA, Biancorosso SL, Camp JD, Hailu SH, Johansen AN, Morris MH, Carlson HN (2023) Tranq-dope\" overdose and mortality: lethality induced by fentanyl and xylazine. Front Pharmacol 14:1280289","journal-title":"Front Pharmacol"},{"key":"6988_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jhsa.2023.04.001","volume":"49","author":"M Soderquist","year":"2024","unstructured":"Soderquist M, Delgado G, Abdelfattah H, Thoder J, Solarz M (2024) Necrotic upper-extremity infections in people who inject drugs: a case series. J Hand Surg Am 49:459\u2013464","journal-title":"J Hand Surg Am"},{"key":"6988_CR47","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/ADM.0000000000001216","volume":"17","author":"A Spadaro","year":"2023","unstructured":"Spadaro A, O\u2019Connor K, Lakamana S, Sarker A, Wightman R, Love JS, Perrone J (2023) Self-reported xylazine experiences: a mixed-methods study of Reddit subscribers. J Addict Med 17:691\u2013694","journal-title":"J Addict Med"},{"key":"6988_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0014-2999(79)90335-2","volume":"58","author":"TC Spaulding","year":"1979","unstructured":"Spaulding TC, Fielding S, Venafro JJ, Lal H (1979) Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur J Pharmacol 58:19\u201325","journal-title":"Eur J Pharmacol"},{"key":"6988_CR49","first-page":"296","volume":"27","author":"DG Spoerke","year":"1985","unstructured":"Spoerke DG, Hall AH, Grimes MJ, Honea BN, Rumack BH (1985) Human overdose with the veterinary tranquilizer xylazine. Vet Hum Toxicol 27:296\u2013296","journal-title":"Vet Hum Toxicol"},{"key":"6988_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111282","volume":"258","author":"CM St Onge","year":"2024","unstructured":"St Onge CM, Canfield JR, Ortiz A, Sprague JE, Banks ML (2024) Xylazine does not enhance fentanyl reinforcement in rats: a behavioral economic analysis. Drug Alcohol Depend 258:111282","journal-title":"Drug Alcohol Depend"},{"key":"6988_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.orthop.2024.01.004","volume":"15","author":"A Sun","year":"2024","unstructured":"Sun A, Borusiewicz M, Johnson TS (2024) Radial nerve palsy in patients presenting with fentanyl\/xylazine wounds of the dorsal forearm: a case series. Orthoplastic Surg 15:15\u201320","journal-title":"Orthoplastic Surg"},{"key":"6988_CR52","doi-asserted-by":"crossref","unstructured":"Sun Y, Darmani NA (2024) A comparative study of the antiemetic effects of alpha(2)-Adrenergic receptor agonists clonidine and Dexmedetomidine against diverse emetogens in the least shrew (Cryptotis parva) model of emesis. Int J Mol Sci 25","DOI":"10.3390\/ijms25094603"},{"key":"6988_CR53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nchembio.64","volume":"4","author":"JP Vilardaga","year":"2008","unstructured":"Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, Lohse MJ (2008) Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol 4:126\u2013131","journal-title":"Nat Chem Biol"},{"key":"6988_CR54","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdcr.2023.04.016","volume":"36","author":"J Wei","year":"2023","unstructured":"Wei J, Wachuku C, Berk-Krauss J, Steele KT, Rosenbach M, Messenger E (2023) Severe cutaneous ulcerations secondary to xylazine (tranq): a case series. JAAD Case Rep 36:89\u201391","journal-title":"JAAD Case Rep"},{"key":"6988_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910290","author":"B Wu","year":"2021","unstructured":"Wu B, Hand W, Alexov E (2021) Opioid addiction and opioid receptor dimerization: structural modeling of the OPRD1 and OPRM1 heterodimer and its signaling pathways. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms221910290","journal-title":"Int J Mol Sci"},{"key":"6988_CR56","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/FBP.0000000000000581","volume":"31","author":"CA Zamarripa","year":"2020","unstructured":"Zamarripa CA, Patel TR, Williams BC, Pareek T, Schrock HM, Prisinzano TE, Freeman KB (2020) The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone\u2019s conditioned rewarding effects in male rats. Behav Pharmacol 31:792\u2013797","journal-title":"Behav Pharmacol"},{"key":"6988_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s002130050035","volume":"148","author":"L Zhang","year":"2000","unstructured":"Zhang L, Walker EA, Sutherland J 2nd, Young AM (2000) Discriminative stimulus effects of two doses of Fentanyl in rats: Pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids. Psychopharmacology 148:136\u2013145","journal-title":"Psychopharmacology"},{"key":"6988_CR58","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fphar.2020.01078","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhang JT, Hang L, Liu T (2020) Mu opioid receptor heterodimers emerge as novel therapeutic targets: recent progress and future perspective. Front Pharmacol 11:1078","journal-title":"Front Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06988-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06988-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:03:38Z","timestamp":1792537418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06988-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["6988"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06988-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.06.25.661558","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare they have no financial interests.","order":4,"name":"Ethics","label":"Financial interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no competing interests to declare that are relevant to the content of this article.","order":5,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}